Autoinflammatory & rare systemic diseases
Effectiveness and probability of full disease control with canakinumab in familial Mediterranean fever: real-world data from the AutoInflammatory Disease Alliance (AIDA) Network
Authors' conclusion
CAN is effective in achieving rapid and sustained clinical and laboratory control in FMF, including stringent endpoints of complete response.
Study context
- Population
- FMF patients treated with canakinumab (CAN), international AIDA network registry dedicated to monogenic autoinflammatory diseases
- Participants
- 158 patients
- Outcome
- Complete control of cardinal disease manifestations and full normalization of laboratory inflammatory markers (complete clinical-laboratory response)
Methodological detailsinternational registry (AIDA network), retrospective and prospective real-world data
- International registry (AIDA network)
- Retrospective and prospective real-world data
Main finding
As reported in the abstract
Complete clinical-laboratory response
Complete response at 3 months
45.6%
Complete response at 12 months
58.6%
Complete response at last follow-up (mean treatment duration 45 months)
55.2%
Observational data: associations, not effects.
Further findings
Partial response
- Partial response at 3 months
- 16.5%
- Partial response at 12 months
- 12.5%
- Partial response at last follow-up
- 16.8%
Complete absence of clinical manifestations
- Observed in more than 80% of patients at each timepoint
Inflammatory markers · 3 months
- Normalized significantly by the 3-month assessment
Factors associated with complete response
- Associated with a relapsing-remitting disease course and fewer annual attacks
- Probability of achieving and maintaining complete response and full laboratory control higher in those reaching these by 3 months, but substantial in others
Organ damage scores
- Nearly all patients maintained stable organ damage scores
Safety
Therapy discontinuation due to inefficacy
- Rare
- ≤6%
Original publication
Effectiveness and probability of full disease control with canakinumab in familial Mediterranean fever: real-world data from the AIDA Network. Rheumatology (Oxford). Published 13 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →